Responsibility in Drug Advertising Act of 2025

This bill, titled the Responsibility in Drug Advertising Act of 2025, aims to significantly amend the Federal Food, Drug, and Cosmetic Act by imposing new restrictions on direct-to-consumer drug advertising . Its primary provision establishes a prohibition on all forms of direct-to-consumer advertising, including on social media platforms, for any newly approved drug for a period of three years following its initial approval. A key exception allows the Secretary to grant a waiver for this prohibition during the third year, provided the drug's sponsor applies and the Secretary determines that such advertising would offer an affirmative value to public health . Furthermore, the bill grants the Secretary ongoing authority to prohibit direct-to-consumer advertising for a drug even after the initial three-year period if significant adverse health effects are identified through post-approval studies or other relevant data. The Secretary is also mandated to revise existing regulations within one year to implement these new restrictions.